春季银行HBV候选人SB 9200在中期研究中表现出良好的安全性

StephenW

Spring Bank's HBV candidate SB 9200 shows favorable safety profile in mid-stage study
May 23, 2017 4:37 PM ET|About: Spring Bank Pharmaceut... (SBPH)|By: Douglas W. House, SA News Editor

Top-line results from a Phase 2a clinical trial, ACHIEVE, assessing Spring Bank Pharmaceuticals' (NASDAQ:SBPH) SB 9200 for the treatment of chronic hepatitis B virus (HBV) infection showed an encouraging safety profile.

There were no serious adverse events observed during the 12-week study. Treatment-emergent adverse events were mild to moderate, with no interferon-like side effects. There were no Grade 3 (serious) laboratory abnormalities, but ALT flares (rapid increases in the liver enzyme) were observed in three patients, but only one was receiving SB 9200. This instance was categorized as a beneficial immune flare because it was associated with a significant reduction in HBV DNA.

Detailed results will be submitted for presentation at a future medical conference.

Management will host a conference call tomorrow morning at 8:00 am ET to discuss the data.

StephenW

春季银行HBV候选人SB 9200在中期研究中表现出良好的安全性
2017年5月23日下午4:37 关于：Spring Bank Pharmaceut ...（SBPH）| 作者：Douglas W. House，SA新闻编辑

评估Spring Bank Pharmaceuticals（纳斯达克股票代码：SBPH）SB 9200用于治疗慢性乙型肝炎病毒（HBV）的2a期临床试验的首选结果，

在12周的研究中没有严重的不良事件。 治疗急性不良反应含量轻微至中度，无干扰素样副作用。 没有3级（严重）实验室异常，但在3例患者中观察到ALT耀斑（肝酶快速增长），但仅有1例接受了SB 9200.这种病例被归类为有益的免疫性耀斑，因为它与 HBV DNA显着减少。

将在未来的医疗会议上提交详细的结果。

管理层将于明天上午8:00在东电中心主持电话会议，讨论数据。